Skip to content

Startup & venture capital news

Microbiotica secures GBP 36m Series C first close

British Business Bank leads funding for an ulcerative colitis study

By /

LinkedInX
Microbiotica: Microbiotica secures GBP 36m Series C first close
Microbiotica official management page; photographer not stated

Microbiotica announced the first close of a GBP 36 million Series C on 16 October 2026. British Business Bank led the financing, joined by Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners. The Cambridge company develops precision medicines based on defined combinations of gut bacteria. Proceeds will advance MB310, an oral capsule containing eight bacterial strains, into Phase 2 development for ulcerative colitis. The planned trial will test whether earlier clinical findings hold in a larger study. Founded in 2016 as a Wellcome Sanger Institute spinout, Microbiotica uses genomic analysis to connect bacterial signatures with patient outcomes.

Keep reading

More Funding

All stories